Richard Rupp1, Gary Joseph Luckasen2, Judith Lee Kirstein3, Jorge E Osorio4, Joseph D Santangelo5, Marsha Raanan6, Mary Kathryn Smith7, Derek Wallace8, Gilad S Gordon9, Dan T Stinchcomb10. 1. Sealy Center for Vaccine Development, University of Texas Medical Branch at Galveston, Galveston, TX, United States. 2. Medical Center of the Rockies Foundation, University of Colorado Health North Research, Loveland, CO, United States. 3. Utah Research Team, Advanced Clinical Research, West Jordan, UT, United States. 4. Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, United States; Scientific Affairs and Policy, Takeda Vaccines, Inc., Deerfield, IL, United States. 5. Operations, Takeda Vaccines Pte. Ltd, Singapore, Singapore. 6. Statistics, Quantitative Sciences, Takeda Development Center Americas Inc., Deerfield, IL, United States. 7. Clinical Testing Laboratory, Takeda Vaccines, Inc., Deerfield, IL, United States. 8. Clinical Development, Takeda Vaccines Pte. Ltd, Singapore, Singapore. 9. Orra Group, LLC, Boulder, CO, United States. 10. Scientific Affairs and Policy, Takeda Vaccines, Inc., Deerfield, IL, United States. Electronic address: dan.stinchcomb@takeda.com.
Abstract
INTRODUCTION: A safe, effective dengue vaccine that can simultaneously induce immunity to all four dengue virus serotypes (DENV-1-4) is a public health priority. A chimeric tetravalent dengue vaccine (TDV) based on an attenuated DENV-2 serotype backbone was evaluated in healthy, flavivirus-seronegative adults. METHODS: In this randomized, multicenter, Phase 1b study conducted in the United States, the safety and immunogenicity of TDV were evaluated in 140 participants aged 18-45 years in six dosing regimen study groups. Participants were injected subcutaneously on Days 0 and 90; placebo (saline) was injected where appropriate to maintain double blinding. Three different TDV dosages (TDV, a vaccine in which TDV-4 had been increased three-fold, and a one-tenth TDV dose), and single or double dosing were evaluated in one and/or both arms. Primary endpoints were solicited and unsolicited adverse events (AEs) and seroconversion rates to DENV-1-4 at Day 120. RESULTS: The severity of all AEs was generally mild. The most common unsolicited AEs were headache (52%), fatigue (43%) and myalgia (29%). The incidence of injection site pain ranged from 29 to 64% and 5 to 52% among study groups after the first and second doses, respectively. At Day 120, the ranges of seroconversion rates among the groups were DEN-1: 84-100%; DEN-2: 96-100%; DEN-3: 83-100%; and DEN-4: 33-77%. More than 80% of participants in each group seroconverted to at least three dengue serotypes. Substantial GMT increases from baseline were observed for DEN-1-3 at all time points from Day 30 onward; DEN-4 GMT increases were lower. Increasing TDV-4 slightly increased DEN-4 GMT, did not impact DEN-2 and DEN-3 GMT, but reduced DEN-1 GMT. Neither multiple dosing in both arms, nor one-tenth TDV dosing meaningfully impacted GMT increases relative to TDV. CONCLUSIONS: All TDV doses and dosing schedules were well tolerated and immunogenic in healthy flavivirus-naive adults (ClinicalTrials.gov NCT01511250).
RCT Entities:
INTRODUCTION: A safe, effective dengue vaccine that can simultaneously induce immunity to all four dengue virus serotypes (DENV-1-4) is a public health priority. A chimeric tetravalent dengue vaccine (TDV) based on an attenuated DENV-2 serotype backbone was evaluated in healthy, flavivirus-seronegative adults. METHODS: In this randomized, multicenter, Phase 1b study conducted in the United States, the safety and immunogenicity of TDV were evaluated in 140 participants aged 18-45 years in six dosing regimen study groups. Participants were injected subcutaneously on Days 0 and 90; placebo (saline) was injected where appropriate to maintain double blinding. Three different TDV dosages (TDV, a vaccine in which TDV-4 had been increased three-fold, and a one-tenth TDV dose), and single or double dosing were evaluated in one and/or both arms. Primary endpoints were solicited and unsolicited adverse events (AEs) and seroconversion rates to DENV-1-4 at Day 120. RESULTS: The severity of all AEs was generally mild. The most common unsolicited AEs were headache (52%), fatigue (43%) and myalgia (29%). The incidence of injection site pain ranged from 29 to 64% and 5 to 52% among study groups after the first and second doses, respectively. At Day 120, the ranges of seroconversion rates among the groups were DEN-1: 84-100%; DEN-2: 96-100%; DEN-3: 83-100%; and DEN-4: 33-77%. More than 80% of participants in each group seroconverted to at least three dengue serotypes. Substantial GMT increases from baseline were observed for DEN-1-3 at all time points from Day 30 onward; DEN-4 GMT increases were lower. Increasing TDV-4 slightly increased DEN-4 GMT, did not impact DEN-2 and DEN-3GMT, but reduced DEN-1GMT. Neither multiple dosing in both arms, nor one-tenth TDV dosing meaningfully impacted GMT increases relative to TDV. CONCLUSIONS: All TDV doses and dosing schedules were well tolerated and immunogenic in healthy flavivirus-naive adults (ClinicalTrials.gov NCT01511250).
Authors: Jesica A Swanstrom; Sandra Henein; Jessica A Plante; Boyd L Yount; Douglas G Widman; Emily N Gallichotte; Hansi J Dean; Jorge E Osorio; Charalambos D Partidos; Aravinda M de Silva; Ralph S Baric Journal: J Infect Dis Date: 2018-05-25 Impact factor: 5.226
Authors: Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores Journal: Clin Microbiol Rev Date: 2022-07-06 Impact factor: 50.129
Authors: Michael K McCracken; Caitlin H Kuklis; Chandrika B Kannadka; David A Barvir; Mark A Sanborn; Adam T Waickman; Hayden C Siegfried; Kaitlin A Victor; Kristin L Hatch; Rafael De La Barrera; Shannon D Walls; Wiriya Rutvisuttinunt; Jeffrey R Currier; Heather Friberg; Richard G Jarman; Gregory D Gromowski Journal: NPJ Vaccines Date: 2021-05-21 Impact factor: 7.344
Authors: Laura J White; Ellen F Young; Mark J Stoops; Sandra R Henein; Elizabeth C Adams; Ralph S Baric; Aravinda M de Silva Journal: PLoS Negl Trop Dis Date: 2021-03-12
Authors: Gokul Swaminathan; Elizabeth A Thoryk; Kara S Cox; Jeffrey S Smith; Jayanthi J Wolf; Marian E Gindy; Danilo R Casimiro; Andrew J Bett Journal: Sci Rep Date: 2016-10-05 Impact factor: 4.379